Accuray shares rise 13.19% premarket after FDA clears ClearRT imaging technology for Radixact platform.

Accuray surged 13.19% in premarket trading following U.S. Food and Drug Administration (FDA) 510(k) clearance for its ClearRT helical kilovoltage CT (kVCT) imaging technology. The approval, announced as a key regulatory milestone, integrates ClearRT into Accuray’s Radixact radiation therapy platform, enabling diagnostic-quality imaging for patient setup and registration. The technology, designed to operate at both kV and megavoltage wavelengths, is expected to be commercially available by spring 2021, according to the vendor. The clearance signals progress in enhancing the company’s radiation oncology solutions, likely boosting investor confidence in its product pipeline and market competitiveness.